Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.
Not Applicable
Recruiting
- Conditions
- Drug-Induced Acute Liver Injury
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2023-02-03
- Target Recruit Count
- 5405
- Registration Number
- NCT05711459
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-01-17
- Target Recruit Count
- 65
- Registration Number
- NCT05686434
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Safety and Efficacy of Oral Etoposide Combined With Antirotinib and Envollizumab in Elderly Patients With Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Progression Free Survival(PFS)
- Interventions
- Drug: Toposide capsules combined with anrotinib and Emvolizumab group
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-01-17
- Target Recruit Count
- 30
- Registration Number
- NCT05685550
Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma
Phase 2
- Conditions
- Recurrent/Refractory Classical Hodgkin's Lymphoma
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-01-13
- Target Recruit Count
- 30
- Registration Number
- NCT05683704
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 30
- Registration Number
- NCT05679050
- Locations
- 🇨🇳
Rui Liu, Tianjin, Tianjin, China
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
Phase 3
- Conditions
- Peripheral T-cell Lymphoma Targeted Therapy
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 200
- Registration Number
- NCT05678933
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Phase 2
Recruiting
- Conditions
- Intrahepatic CholangiocarcinomaGemcisDurvalumab
- Interventions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2023-01-05
- Target Recruit Count
- 70
- Registration Number
- NCT05672537
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Target Recruit Count
- 100
- Registration Number
- NCT05651672
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours
Phase 1
Recruiting
- Conditions
- Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Target Recruit Count
- 30
- Registration Number
- NCT05644392
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Target Recruit Count
- 30
- Registration Number
- NCT05644379
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath